JCR Pharmaceuticals Joins “Relay For Life of Ashiya” in Support of the Cancer Community

Hyogo, Japan – September 10, 2026 – JCR Pharmaceuticals Co., Ltd. (TSE 4552; “JCR”) sponsored and participated in “Relay For Life of Ashiya,” held in Ashiya, Hyogo, on September 5 and 6. The community charity event is organized by local volunteers and managed by the Relay for Life Kansai Executive Committee and the Japan Cancer Society under license from the American Cancer Society.

Relay For Life brings communities together to support people living with cancer and their families. Funds raised through sponsorships and donations support Japan Cancer Society initiatives including research into new treatments and drug development, free cancer counseling, and efforts to encourage cancer screening. JCR continues to support the event through its sponsorship and participation.

This year, approximately 50 JCR employees and family members from across the company joined the Relay Walk and Candlelight Run. Walking through the night toward dawn, they reflected on what it means for patients to face cancer every day as they ran and walked forward together, one step at a time.

Employees shared reflections such as: “Taking part gave me many new insights and much to learn. It was an invaluable opportunity to gain a firsthand sense of the thoughts and feelings of patients, their families and supporters, and the warmth of the connections among them.” “Running through the night was tough, but the encouragement all around the venue kept me going, one step at a time. I was glad to run even one kilometer farther and contribute more to the fundraising effort.”

JCR will continue to take on difficult healthcare challenges beyond rare disease, while strengthening ties with local communities and contributing to society.

About Relay For Life

Relay For Life began in 1985, when a surgeon in the United States ran around a track for 24 hours to raise donations for the American Cancer Society. His effort symbolized the reality that people with cancer face their illness every hour of every day. What started as a single act of solidarity has
grown into a global movement that inspires courage and hope by bringing people together to walk, talk, and share. Today, Relay For Life is held in approximately 1,700 locations across 37 countries worldwide.
In Japan, Relay For Life continues to expand nationwide, with approximately 52 events scheduled in 2026. Ashiya has officially hosted the event as an overnight gathering since 2007, and this year marks its 20th edition under the theme, “This is where I took a step forward. This is where I meet you again.”
For more information, please visit the official website (Japanese only):
Relay For Life of Ashiya: https://relayforlife.jp/ashiya/.

About JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceutical company that develops treatments that go beyond rare diseases to solve the world’s most complex healthcare challenges. We continue to build upon our 50-year legacy in Japan while expanding our global footprint into the U.S., Europe, and Latin America. We improve patients’ lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. Our core values – Putting people first, Forging our own path, Always advancing, and Committed to excellence – mean that the work we do benefits all our stakeholders, including partners, patients and employees. We strive to expand the possibilities for patients while accelerating medical advancement at a global level. For more information, please visit JCR’s global website: https://jcrpharm.com/.